8 unknown, 5 recruiting, 4 completed, 4 suspended. 14 Not applicable, 9 Phase 1, 3 Early Phase 1, 3 Phase 2.
Follow Bioray Laboratories: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal CAR-T Cell Therapy for MM Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection - Multiple Myeloma, Multiple Myeloma in Relapse | Not applicable | Recruiting | Bioray Laboratories | 6 | 2025-04-10 | 2025-12-01 |
| Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC PSMA-UCAR T (BRL-302) - Metastatic Prostate Cancer, Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 3 | 2025-03-27 | 2026-07-23 |
| Universal CAR-T Cell Therapy for NHL BRL-301 - Non-hodgkin Lymphoma,B Cell | Not applicable | Recruiting | Bioray Laboratories | 6 | 2025-03-11 | 2025-11-25 |
| Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T - Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized | Early Phase 1 | Not yet recruiting | Xuanwu Hospital, Beijing | 25 | 2025-02-28 | 2025-01-01 |
| Long-term Follow-up Study of BRL-101 for TDT Assessments - Thalassemia, Beta | Recruiting | Bioray Laboratories | 45 | 2024-12-08 | 2026-07-21 | |
| The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD Universal BCMA-CD19 CART - Autoimmune Disease | Phase 1 | Unknown | Bioray Laboratories | 18 | 2024-11-25 | 2024-11-12 |
| Universal CAR-T Cell Therapy for Refractory Lupus Nephritis BCMA CART + CD19 CART - Lupus Nephritis | Early Phase 1 | Unknown | Bioray Laboratories | 10 | 2024-11-25 | 2024-11-08 |
| Clinical Study of BRL-101 in Severe SCD BRL-101 - Sickle Cell Disease | Not applicable | Unknown | Bioray Laboratories | 3 | 2024-07-29 | 2024-07-31 |
| Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease BRL-101 autologous hematopoietic stem and progenitor cells injection - Sickle Cell Disease | Not applicable | Unknown | Bioray Laboratories | 1 | 2024-06-14 | 2024-06-03 |
| Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease BRL-101 - Sickle Cell Disease | Not applicable | Unknown | Bioray Laboratories | 5 | 2024-04-20 | 2024-03-19 |
| Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC Enhanced autologous PSMA-CAR T - Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer | Early Phase 1 | Active not recruiting | Shanghai Changzheng Hospital | 18 | 2024-03-03 | 2026-07-23 |
| Efficacy and Safety Evaluation of PD1-BCMA-CART PD1-BCMA-CART - Multiple Myeloma | Not applicable | Unknown | Bioray Laboratories | 9 | 2024-03-01 | 2024-01-05 |
| Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells γ-globin reactivated autologous hematopoietic stem cells - Thalassemia Major | Not applicable | Suspended | Bioray Laboratories | 5 | 2023-12-25 | 2024-02-28 |
| Safety and Efficacy Evaluation of Next-generation CD19-UCART CD19-UCART - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 | Unknown | Bioray Laboratories | 20 | 2023-12-20 | 2023-01-27 |
| Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus BRL-301 - Systemic Lupus Erythematosus (SLE) | Not applicable | Unknown | Bioray Laboratories | 12 | 2023-08-14 | 2024-09-27 |
| Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases BRL-301 - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Not applicable | Enrolling by invitation | Bioray Laboratories | 15 | 2023-05-17 | 2024-11-20 |
| The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection - Non-hodgkin Lymphoma,B Cell | Phase 1 | Recruiting | Bioray Laboratories | 18 | 2023-04-25 | 2025-11-25 |
| Long-term Follow-up Study of BHC001 for TDT Assessments - Thalassemia, Beta | Recruiting | Bioray Laboratories | 6 | 2022-12-14 | 2024-03-18 | |
| Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia BRL-101 - Beta-Thalassemia | Phase 1 / Phase 2 | Active not recruiting | Bioray Laboratories | 39 | 2022-11-02 | 2026-07-21 |
| PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer PD1-PSMA-CART cells - Castrate-Resistant Prostate Cancer | Phase 1 | Completed | Zhejiang University | 3 | 2021-12-23 | 2023-07-17 |
Showing 20 of 28. Sign in to see all of them.
Multiple Myeloma (4) · beta-Thalassemia (4) · Anemia, Sickle Cell (3) · Lupus Erythematosus, Systemic (2) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Antiphospholipid Syndrome (1) · Autoimmune Diseases (1) · Lupus Nephritis (1) · Lymphoma, B-Cell (1) · Multiple Sclerosis (1) · Myasthenia Gravis (1) · Myositis (1) · Neoplasm Metastasis (1) · Neuromyelitis Optica (1)
China (23)
Rongmei Liang, PhD (2) · Yi Zhang, Professor (2) · Yunxiao Xu, MD (2) · Aibin Liang, PhD (1) · Bin Fu, Prof. (1) · He Huang, Prof (1) · He Huang, Professor (1) · Ping Li, PhD (1) · Shancheng Ren, MD, PhD (1) · Shancheng Ren, Professor (1) · Wei Li (1) · Weijia Fang, MD (1) · Xiaochen Wang, PhD (1) · Xiaohui Wang, PhD (1)
PMID 34175041, PMID 35468680, PMID 35922667, PMID 36045296, PMID 37192741, PMID 37251628, PMID 39013470, PMID 40446794